COMPANY

Opna Bio

HQ: Lafayette, CA (US office) source · opnabio.com ↗

Keywords: oncology cancer small molecule Relapsed Multiple Myeloma Refractory Multiple Myeloma Metastatic Castration-resistant Prostate Cancer Gynecologic Neoplasms Epithelial Ovarian Cancer Small Cell Lung Cancer Uveal Melanoma Ovarian Clear Cell Carcinoma Non-Hodgkin Lymphoma Diffuse Large B Cell Lymphoma Follicular Lymphoma Relapsed Acute Myeloid Leukemia (AML) Refractory Acute Myeloid Leukemia (AML) High-risk Myelodysplastic Syndrome (MDS) PLX2853 OPN-6602

Location: Lafayette, CA (US office) · source · Oct 15, 2026

Profile checked Oct 10, 2026

5Trials (company is sponsor)

Timeline

Aug 22, 2024 Trial start Phase 1: Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma source ↗
Sep 21, 2020 Trial start Phase 1/Phase 2: PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) source ↗
Aug 11, 2020 Trial start Phase 1/Phase 2: PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer source ↗
Mar 19, 2019 Trial start Phase 1: A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome source ↗
Sep 12, 2017 Trial start Phase 1: A Study of PLX2853 in Advanced Malignancies. source ↗

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT06433947	Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma	Phase 1	Recruiting	Aug 22, 2024	2026-07 (estimated)
NCT04556617	PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Phase 1/Phase 2	Terminated	Sep 21, 2020	May 24, 2022 (actual)
NCT04493619	PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer	Phase 1/Phase 2	Terminated	Aug 11, 2020	Apr 25, 2022 (actual)
NCT03297424	A Study of PLX2853 in Advanced Malignancies.	Phase 1	Completed	Sep 12, 2017	Jun 7, 2021 (actual)
NCT03787498	A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome	Phase 1	Completed	Mar 19, 2019	Jun 30, 2021 (actual)